The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

  1. Aragón-Herrera, A.
  2. Otero-Santiago, M.
  3. Anido-Varela, L.
  4. Moraña-Fernández, S.
  5. Campos-Toimil, M.
  6. García-Caballero, T.
  7. Barral, L.
  8. Tarazón, E.
  9. Roselló-Lletí, E.
  10. Portolés, M.
  11. Gualillo, O.
  12. Moscoso, I.
  13. Lage, R.
  14. González-Juanatey, J.R.
  15. Feijóo-Bandín, S.
  16. Lago, F.
Journal:
Frontiers in Pharmacology

ISSN: 1663-9812

Year of publication: 2022

Volume: 13

Type: Article

DOI: 10.3389/FPHAR.2022.827033 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus